<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE339nnn/GSE339275/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339275</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Peptide-targeted lipid nanoparticles orchestrating IFN-γ and cisplatin crosstalk eliminate ovarian cancer [RNA-seq]</name><description>Ovarian cancer remains refractory to current immunotherapies, largely due to poor tumor targeting, immunosuppressive feedback, and the absence of durable memory responses. Here, we develop a peptide-targeted lipid nanoparticle (ptLNP) platform modified with an FSHR-affinity peptide (Pep LLV) that enables ovarian-directed co-delivery of interferon-gamma (IFN‑γ) mRNA and cisplatin (CDDP). In an orthotopic mouse model, ptLNP-mediated IFN‑γ delivery suppresses tumor progression but upregulates intraovarian PD‑1 expression, creating an adaptive resistance loop that is relieved by co-delivered anti‑PD‑1 antibody. Single-cell RNA sequencing reveals that CDDP eliminates divergent tumor differentiation trajectories and enforces G2/M arrest, which prevents mitotic dilution of the IFN‑γ effector IRF1 and sustains pro-apoptotic signaling. This mechanism is validated by IRF1 gain- and loss-of-function experiments, demonstrating that IRF1 is both sufficient and necessary for the synergistic effect. In T-cell-deficient xenograft models, the IFN‑γ–CDDP combination achieves complete tumor regression, indicating direct cytostatic activity independent of adaptive immunity. Post-treatment IL‑12 boosting further establishes long-term CD4⁺ and CD8⁺ memory T cell responses, conferring protection against tumor re-challenge. Collectively, this study presents a modular platform that orchestrates cytokine therapy, checkpoint blockade, chemotherapy, and memory immunity, providing a mechanistic framework for combinatorial immunotherapy against refractory ovarian cancer.</description><dates><publication>2026/07/28</publication></dates><accession>GSE339275</accession><cross_references><GSM>GSM9892263</GSM><GSM>GSM9892252</GSM><GSM>GSM9892253</GSM><GSM>GSM9892264</GSM><GSM>GSM9892261</GSM><GSM>GSM9892251</GSM><GSM>GSM9892262</GSM><GSM>GSM9892270</GSM><GSM>GSM9892260</GSM><GSM>GSM9892269</GSM><GSM>GSM9892258</GSM><GSM>GSM9892259</GSM><GSM>GSM9892256</GSM><GSM>GSM9892267</GSM><GSM>GSM9892268</GSM><GSM>GSM9892257</GSM><GSM>GSM9892265</GSM><GSM>GSM9892254</GSM><GSM>GSM9892266</GSM><GSM>GSM9892255</GSM><GPL>28457</GPL><GSE>339275</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>